MX2015009153A - Uso de agonistas del receptor nicotinico de acetilcolina alfa 7. - Google Patents

Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.

Info

Publication number
MX2015009153A
MX2015009153A MX2015009153A MX2015009153A MX2015009153A MX 2015009153 A MX2015009153 A MX 2015009153A MX 2015009153 A MX2015009153 A MX 2015009153A MX 2015009153 A MX2015009153 A MX 2015009153A MX 2015009153 A MX2015009153 A MX 2015009153A
Authority
MX
Mexico
Prior art keywords
receptor agonists
alpha
acetylcholine receptor
nicotinic acetylcholine
amelioration
Prior art date
Application number
MX2015009153A
Other languages
English (en)
Inventor
Dominik Feuerbach
Markus Fendt
Cristina Lopez-Lopez
Kevin Hall Mcallister
Judit Sovago
Markus Weiss
Donald Johns
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2015009153A publication Critical patent/MX2015009153A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La invención se refiere al uso de ciertos agonistas del receptor nicotínico de acetilcolina alfa 7 para el tratamiento, mejora, prevención o retraso del avance de la fatiga.
MX2015009153A 2013-01-15 2014-01-13 Uso de agonistas del receptor nicotinico de acetilcolina alfa 7. MX2015009153A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361752765P 2013-01-15 2013-01-15
PCT/IB2014/058224 WO2014111837A1 (en) 2013-01-15 2014-01-13 Use of alpha 7 nicotinic acetylcholine receptor agonists

Publications (1)

Publication Number Publication Date
MX2015009153A true MX2015009153A (es) 2016-03-04

Family

ID=50070638

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009153A MX2015009153A (es) 2013-01-15 2014-01-13 Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.

Country Status (11)

Country Link
EP (1) EP2945637B1 (es)
JP (2) JP2016508159A (es)
KR (1) KR101879919B1 (es)
CN (1) CN105246485B (es)
BR (1) BR112015016992A8 (es)
CA (1) CA2898045C (es)
ES (1) ES2865736T3 (es)
JO (1) JOP20140008B1 (es)
MX (1) MX2015009153A (es)
TW (1) TWI659740B (es)
WO (1) WO2014111837A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202002990XA (en) * 2017-08-04 2020-05-28 Skyhawk Therapeutics Inc Methods and compositions for modulating splicing
AU2019401576A1 (en) * 2018-12-17 2021-06-24 Société des Produits Nestlé S.A. Formulations for egg oral immunotherapy, methods of manufacture, and treatments for egg allergy
JP2022521467A (ja) 2019-02-05 2022-04-08 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19854147A1 (de) * 1998-11-24 2000-05-25 Basf Ag Verwendung von N-substituierten Azabicycloalkan-Derivaten zur Verwendung bei der Bekämpfung der Cocainsucht
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
SE0201943D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New use
CA2493245A1 (en) * 2002-08-14 2004-02-26 Neurosearch A/S Novel quinuclidine derivatives and their use
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
ES2405594T3 (es) 2002-09-25 2013-05-31 Memory Pharmaceuticals Corporation Idazoles, benzotiazoles y benzisotiazoles, y preparación y usos de los mismos
WO2005044267A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes ii
JP2007510645A (ja) 2003-10-31 2007-04-26 アストラゼネカ アクチボラグ アルキン類ｉ
WO2005044265A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes iii
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
WO2006065233A1 (en) 2004-12-10 2006-06-22 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20070149547A1 (en) 2004-02-12 2007-06-28 Celine Bonnefous Bipyridyl amides as modulators of metabotropic glutamate receptor-5
GB0412019D0 (en) 2004-05-28 2004-06-30 Novartis Ag Organic compounds
PE20060437A1 (es) * 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) * 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
GB0521508D0 (en) * 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525672D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
WO2007071358A1 (en) 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
DE602007004307D1 (de) * 2006-02-16 2010-03-04 Neurosearch As Enantiomerenreine chinuclidinyloxy-pyridazine und ihre verwendung als nikotin-acetylcholin-rezeptorliganden
TW200813067A (en) 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
CN101448825A (zh) 2006-05-19 2009-06-03 艾博特公司 Cns活性的稠合的双环杂环取代的氮杂双环烷烃衍生物
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009066107A1 (en) 2007-11-21 2009-05-28 Astrazeneca Ab Use of a nicotinic receptor agonist
WO2010043515A1 (en) 2008-10-13 2010-04-22 F. Hoffmann-La Roche Ag Diazonium-free method to make an indazole intermediate in the synthesis of bicyclic 5-(trifluormethoxy)-1h-3-indazolecarboxylic acid amides
JP5657556B2 (ja) 2008-11-11 2015-01-21 ターガセプト，インコーポレイテッド α７選択的リガンドを用いる治療
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
EP2959902A1 (en) * 2009-07-23 2015-12-30 Novartis AG Use of azabicycloalkyl derivatives for the treatment or prevention of ataxia
JO3250B1 (ar) * 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
CN103442701A (zh) * 2011-01-27 2013-12-11 诺瓦提斯公司 烟碱乙酰胆碱受体α7激活剂的用途

Also Published As

Publication number Publication date
CN105246485B (zh) 2019-03-15
JP6657534B2 (ja) 2020-03-04
JP2016508159A (ja) 2016-03-17
CN105246485A (zh) 2016-01-13
WO2014111837A1 (en) 2014-07-24
BR112015016992A8 (pt) 2018-01-23
EP2945637B1 (en) 2021-03-10
ES2865736T3 (es) 2021-10-15
BR112015016992A2 (pt) 2017-07-11
CA2898045C (en) 2018-08-28
TWI659740B (zh) 2019-05-21
TW201442708A (zh) 2014-11-16
KR20150105468A (ko) 2015-09-16
JOP20140008B1 (ar) 2021-08-17
EP2945637A1 (en) 2015-11-25
CA2898045A1 (en) 2014-07-24
JP2018021042A (ja) 2018-02-08
KR101879919B1 (ko) 2018-07-18

Similar Documents

Publication Publication Date Title
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
HK1254358A1 (zh) 用於治療突觸核蛋白病的藥劑、用途和方法
PH12017500877B1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
PH12016501763A1 (en) Multispecific antibodies
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MY176855A (en) Anti-jagged1 antibodies and methods of use
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
PH12017501864A1 (en) Compositions and methods for treating autism
IL271728A (en) Materials, uses and treatment methods
GB201512215D0 (en) Agents,uses and methods
MX2017013729A (es) Deteccion especifica de isoformas de clusterina.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
IL251880A0 (en) Preparations for the treatment of acute, post-operative or chronic pain and methods of using them
MX2016015280A (es) Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
MX2015009153A (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
MX2017010526A (es) Mezclas de aceite, procesos para la preparacion de estas y su uso en formulas.